SCHEMBL3477796

SCHEMBL3477796

O=C(NCCc1ccccn1)Nc1[nH]c2ccc(Br)cc2c1S(=O)(=O)N1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.49
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 3/20 0.41
CNR1 P21554 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CYP3A4 P08684 1/20 0.41
PTGFR P43088 1/20 0.41
KMT2A Q03164 2/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
AGTR1 P30556 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3476812 0.92 NPC1 (0.50) TSHRALDH1A1SMN1; SMN2NPC1KMT2A
SCHEMBL3477801 0.87 ALDH1A1 (0.43) TSHRALDH1A1SMN1; SMN2KDM4EPOLB
SCHEMBL3477008 0.84 RAB9A (0.49) TSHRALDH1A1SMN1; SMN2NPC1KMT2A
SCHEMBL3476809 0.84 KDM4E (0.41) ALDH1A1SMN1; SMN2CNR1CYP3A4KMT2A
SCHEMBL3478247 0.83 L3MBTL1 (0.41) ALDH1A1SMN1; SMN2KMT2AKDM4EPOLB
SCHEMBL3476757 0.82 NAMPT (0.52) ALDH1A1SMN1; SMN2CNR1CA12CA9
SCHEMBL3477440 0.81 LMNA (0.43) ALDH1A1SMN1; SMN2CNR1KMT2ATDP1
SCHEMBL3477830 0.81 LMNA (0.41) CNR1KMT2ATDP1MAPT
SCHEMBL3476368 0.80 NAMPT (0.54) ALDH1A1NPC1KMT2AKDM4EMAPT
SCHEMBL3596925 0.79 NPC1 (0.52) TSHRALDH1A1SMN1; SMN2NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-15 US claimed
EP-1898927-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2008-03-19 EP claimed
WO-2007002481-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-01-04 WO claimed
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors RNGTT, RTF1, POLR1E TSHR 2169/4885ALDH1A1 1178/4885SMN1; SMN2 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.